"A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression,1 according to Joyce A. O’Shaughnessy, MD. Nearly 36% of the samples were from patients with triple-negative breast cancer (TNBC), making the study the largest genomic analysis in that disease setting to date.
The clues yielded through the analysis confirm the utility of multiplatform molecular profiling in identifying targets that could help oncologists direct patients who have metastatic disease, or who are not responding to standard therapies, into clinical trials, said O’Shaughnessy. In some instances, drugs aimed at these targets already have been approved.
O’Shaughnessy, who is chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center, Texas Oncology and US Oncology, presented findings from the analysis at the 2013 San Antonio Breast Cancer Symposium (SABCS).1
She discussed her research in an interview in advance of the 31st Annual Miami Breast Cancer Conference (MBCC) in March, where she served as a faculty member. O’Shaughnessy’s expertise includes using emerging technologies to explore novel therapies, particularly for TNBC. Her presentation was entitled “Human Subject Implications of Genomic Profiling of Tumors.”
The clinical utility of next-generation sequencing for managing patients with high-risk or metastatic breast cancer continues to progress with the development of gene expression assays, and genomic profiling of newly diagnosed patients in these settings “will increasingly allow for early intervention with rational targeted therapies that could very significantly improve patients’ outcomes,” O’Shaughnessy said in her MBCC presentation."
Via Susan Zager